# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D), the system includes ...
Genpact's deep domain knowledge and data expertise enables embecta's vision to make a meaningful impact in the healthca...
Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The comp...
https://www.ft.com/content/4aa65f0f-dcdf-4849-bd87-b81b23961fc1Diabetes device maker Embecta has hired advisers to explore a po...